MK-4827 tosylate

CAS No. 1038915-73-9

MK-4827 tosylate( Niraparib tosylate | MK 4827 tosylate | MK4827 tosylate )

Catalog No. M10196 CAS No. 1038915-73-9

A highly potent PARP inhibitor with IC50 of 3.8 nM/2.1 nM for PARP1/PARP2.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 34 In Stock
5MG 55 In Stock
10MG 77 In Stock
25MG 107 In Stock
50MG 135 In Stock
100MG 219 In Stock
500MG 534 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    MK-4827 tosylate
  • Note
    Research use only, not for human use.
  • Brief Description
    A highly potent PARP inhibitor with IC50 of 3.8 nM/2.1 nM for PARP1/PARP2.
  • Description
    A highly potent PARP inhibitor with IC50 of 3.8 nM/2.1 nM for PARP1/PARP2; inhibits PARP activity with EC50=4 nM in a whole cell assay, and inhibits proliferation of cancer cells with mutant BRCA-1 and BRCA-2 with CC50 in the 10?100 nM range; well tolerated in vivo and demonstrates efficacy as a single agent in a xenograft model of BRCA-1 deficient cancer.Ovarian Cancer Approved(In Vitro):Niraparib (MK-4827) inhibits PARP activity with EC50=4 nM and EC90=45 nM in a whole cell assay. MK-4827 inhibits proliferation of cancer cells with mutant BRCA-1 and BRCA-2 with CC50 in the 10?100 nM range. MK-4827 displays excellent PARP 1 and 2 inhibition with IC50=3.8 and 2.1 nM, respectively, and in a whole cell assay. To validate that Niraparib (MK-4827) inhibits PARP in these cell lines, A549 and H1299 cells are treated with 1 μM Niraparib (MK-4827) for various times and measured PARP enzymatic activity using a chemiluminescent assay. The results show that Niraparib (MK-4827) inhibits PARP within 15 minutes of treatment reaching about 85% inhibition in the A549 cells at 1 h and about 55% inhibition at 1 h for the H1299 cells.(In Vivo):Niraparib (MK-4827) is well tolerated and demonstrates efficacy as a single agent in a xenograft model of BRCA-1 deficient cancer. Niraparib (MK-4827) is well tolerated in vivo and demonstrates efficacy as a single agent in a xenograft model of BRCA-1 deficient cancer. Niraparib (MK-4827) is characterized by acceptable pharmacokinetics in rats with plasma clearance of 28 (mL/min)/kg, very high volume of distribution (Vdss=6.9 L/kg), long terminal half-life (t1/2=3.4 h), and excellent bioavailability, F=65%. Niraparib (MK-4827) enhances radiation response of p53 mutant Calu-6 tumor in both cases, with the single daily dose of 50 mg/kg being more effective than 25 mg/kg given twice daily.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    Niraparib tosylate | MK 4827 tosylate | MK4827 tosylate
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    PARP
  • Recptor
    PARP1|PARP2
  • Research Area
    Cancer
  • Indication
    Ovarian Cancer

Chemical Information

  • CAS Number
    1038915-73-9
  • Formula Weight
    492.5899
  • Molecular Formula
    C26H28N4O4S
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: ≥ 490 mg/mL
  • SMILES
    CC1=CC=C(C=C1)S(=O)(=O)O.C1CC(CNC1)C2=CC=C(C=C2)N3C=C4C=CC=C(C4=N3)C(=O)N
  • Chemical Name
    2H-Indazole-7-carboxamide, 2-[4-(3S)-3-piperidinylphenyl]-, 4-methylbenzenesulfonate (1:1)

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Jones P, et al. J Med Chem. 2009 Nov 26;52(22):7170-85. 2. Bridges KA, et al. Oncotarget. 2014 Jul 15;5(13):5076-86. 3. Mirza MR, et al. N Engl J Med. 2016 Dec 1;375(22):2154-2164.
molnova catalog
related products
  • Rucaparib phosphate

    An inhibitor of PARP with Ki of 1.4 nM for PARP1 in a cell-free assay.

  • PARP-1-IN-3

    PARP-1-IN-3 is a potent PARP-1 inhibitor that inhibits PARP-1 and PARP-2 with IC50 values of 0.25 nM and 2.34 nM, respectively.

  • AG-14361

    AG14361 is a potent inhibitor of PARP1 with Ki of <5 nM. It is at least 1000-fold more potent than the benzamides.